Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 14

1799P - Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi)

Date

21 Oct 2023

Session

Poster session 14

Topics

Laboratory Diagnostics;  Translational Research

Tumour Site

Prostate Cancer

Presenters

Steven Yip

Citation

Annals of Oncology (2023) 34 (suppl_2): S954-S1000. 10.1016/S0923-7534(23)01946-4

Authors

S.M. Yip1, A.J.W. Gibson2, M. Kolinsky3, K. Takemura4, T. Tucker5, M. Freeman6, E. Khosh Kish7, P. Bose8, M. Dean9, T.A. Bismar10, D.Y.C. Heng11, J..D. Ruether12, S. North13, N. Alimohamed14, N.S. Basappa15, S. Karim16, A. Medina Martin17, A. Kinnaird18, K.N.N. Chi19, S.E. El Hallani20

Author affiliations

  • 1 Oncology Dept., Tom Baker Cancer Centre, T2N4n2 - Calgary/CA
  • 2 Faculty Of Medicine; Department Of Oncology, University of Calgary, T2N4n2 - Calgary/CA
  • 3 Faculty Of Medicine; Department Of Oncology, University of Alberta - FoMD, T6G 2R7 - Edmonton/CA
  • 4 Oncology Dept., Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 5 Pathology And Laboratory Medicine, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 6 Oncology, Tom Baker Cancer Centre, t2n4n2 - Calgary/CA
  • 7 Oncology, Arnie Charbonneau Cancer Institute - University of Calgary, T2N 4Z6 - Calgary/CA
  • 8 Department Of Oncology, Arnie Charbonneau Cancer Institute - University of Calgary, T2N 4Z6 - Calgary/CA
  • 9 Oncology, University of Calgary, T2N 4N2 - Calgary/CA
  • 10 Pathology And Lab Medicine, Faculty of Medicine, University of Calgary, T2V 4T9 - Calgary/CA
  • 11 Oncology Department, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 12 Medical Oncology Department, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 13 Medical Oncology Department, University of Alberta Cross Cancer Institute, T6G 1Z2 - Edmonton/CA
  • 14 Medicine Department, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 15 Medical Oncology Department, Cross Cancer Institute, T6G 1Z2 - Edmonton/CA
  • 16 Department Of Oncology, University of Calgary - Oncology, T2N 4N2 - Calgary/CA
  • 17 Apcari, University of Alberta, T6G 2R3 - Edmonton/CA
  • 18 Dept Of Urology, University of Alberta, T6G 2R3 - Edmonton/CA
  • 19 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 20 Pathology And Lab Medicine, University of Alberta - FoMD, T6G 2R7 - Edmonton/CA

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1799P

Background

Metastatic castration resistant prostate cancer (mCRPC) patients (pts) with HRR alterations (HRR+) benefit from PARPi. We aimed to elucidate the RW outcomes and impact of streamlined access to a biomarker driven tx approach.

Methods

In a multicentre prospective mPCa cohort study, cell free DNA next generation sequencing (cfDNA NGS) was performed using accredited assays (BC Cancer, Foundation Medicine, Alberta panel). Time to CRPC was compared between HRR+ and negative/unknown status (HRR0) using log rank test. In olaparib tx pts, ≥50% PSA decline, radiographic progression free survival (rPFS), serious adverse events (SAE), and overall survival (OS) were examined.

Results

Of 119 pts, 41 (35%) were HRR+ (23 BRCA2, 14 ATM, 5 CDK12, 3 CHEK2, 2 PPP2R2A, 1 BRCA1, 1 PALB2). Median age at diagnosis was 64 yrs, 45% had Gleason ≥ 8, and 13% were non-caucasian. HRR+ pts had a shorter time to CRPC than HRR0 pts (13.7 vs 31.3 months; HR: 2.2; p=0.001). 28 HRR+ pts (19 BRCA2, 8 ATM, 1 BRCA1) received olaparib, demonstrating a trend towards improved OS from mCRPC compared to HRR+ pts without PARPi (38.1 vs 17.4 mo, p=0.20). In 9 HRR+ pts without PARPi, 7 had androgen receptor pathway inhibitor (ARPi) tx and taxane, 1 had ARPi, and 1 had docetaxel. 50% of pts received olaparib after ≥2 systemic tx lines. A longer OS trend was observed in pts receiving 1st line mCRPC olaparib tx than pts receiving olaparib in later tx lines (17.2 vs 11.1 mo, p=0.07). OS from mCRPC was similar in HRR0 and olaparib tx HRR+ pts (37.4 vs 38.1 mo, p=0.70). In olaparib tx pts, median OS post initiation was 11.7 mo, rPFS was 5.4 mo, 36% had ≥50% PSA decline, and 29% had ≥30 days tx beyond PSA progression (PCWG3 criteria). SAE occurred in 39%; 4 pts required transfusion for anemia. Of 8 pts receiving additional systemic tx, 6 had taxane- and 2 had platinum-based chemotherapy.

Conclusions

In this study of heavily pre-treated mPCa pts, RW rPFS and OS on olaparib were reduced compared to clinical trials. Similar OS was seen in olaparib tx HRR+ and HRR0 pts, despite historically poorer prognosis in HRR+ pts. These results demonstrate that a biomarker driven tx approach and earlier access to PARPi may improve outcomes in HRR+ pts.

Clinical trial identification

Editorial acknowledgement

This was an ESCR performed with AstraZeneca funding support and collaboration.

Legal entity responsible for the study

The authors.

Funding

AstraZeneca.

Disclosure

S.M. Yip: Financial Interests, Personal, Advisory Board: Amgen, BMS, Novartis, Pfizer, Hoffman-La Roche, Ipsen; Financial Interests, Personal, Research Funding, Includes ad board/consultancy: Astellas, AstraZeneca, Merck, Bayer, Janssen; Financial Interests, Personal, Other, consultancy: Oncohelix. M. Kolinsky: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Merck, Janssen; Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, BMS, Eisai, Ipsen, Merck, Janssen; Financial Interests, Institutional, Research Grant: Janssen, AstraZeneca. T. Tucker: Financial Interests, Institutional, Invited Speaker: AstraZeneca, Pfizer; Financial Interests, Institutional, Research Grant: Pfizer. P. Bose: Financial Interests, Personal, Ownership Interest, I am a co-founder and director in OncoHelix Inc: Oncohelix. T.A. Bismar: Financial Interests, Personal, Other, advisory role: xpherabio; Financial Interests, Institutional, Funding, funding support for fellow: AstraZeneca. D.Y.C. Heng: Financial Interests, Personal, Advisory Board: Pfizer, Merck, BMS, Ipsen, Novartis, AstraZeneca, Roche; Financial Interests, Personal, Steering Committee Member: Exilexis; Financial Interests, Institutional, Local PI: BMS, Pfizer, Ipsen. S. North: Financial Interests, Personal, Advisory Board, honoraria: Astellas, BMS, Janssen, Merck, Roche, Sanofi, Bayer, AstraZeneca; Financial Interests, Institutional, Local PI, per case funding: Sanofi, AstraZeneca, Ipsen, Astellas. N. Alimohamed: Financial Interests, Personal, Advisory Board: Bayer, Seagen, EMD Serono, BMS, Gilead. N.S. Basappa: Financial Interests, Personal, Advisory Board: Ipsen, Eisai, Pfizer, AstraZeneca, Janssen Inc, EMD Serono, Astellas, Bayer, BMS, Seagen, Takeda; Financial Interests, Institutional, Research Grant, Research Grant: Ipsen; Other, Other, Travel grant/support: Ipsen; Other, Other, Travel Grant/support: Eisai. K.N.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. S.E. El Hallani: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Full or part-time Employment: Alberta Precision Labs; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.